Ansu Satpathy
1.2K posts
@Satpathology
Professor @Stanford, Investor @Wing_VC Founder @CartographyBio @Immunaitech @Arpelos @SantaAnaBio
How specific are therapeutic monoclonal antibodies, really? In our new paper, @Yile_Dai led a collaboration with Adimab to profile 174 FDA-approved and clinical-stage mAbs against 6,172 human extracellular proteins. What we found surprised us.🧵 sciencedirect.com/science/articl…
Big news! I’m joining @AsteraInstitute as CEO of Radial, their new life sciences division. How we fund, do, and build upon science has long needed an update. At Radial, we design, fund, and operate programs that tackle foundational scientific problems while simultaneously testing better ways to do science.
Just posted a preprint on a huge new single-cell study of Parkinson’s and its application to understanding noncoding variation. 🧵below. Led by Shreya Menon and Adam Turner and in collab w/ GP2 (@ASAP_Research), @BelloyMichael, @ZihHuaFang and others. doi.org/10.64898/2026.…
If you’re thinking about the future of biotech, this conversation is for you. In the latest episode of The Long Run podcast with @ldtimmerman of @timmermanreport, Wing Venture Partner Dr. Ansu @Satpathology shares why he remains bullish on U.S. biomedical innovation. Ansu works at the intersection of academia and venture and focuses on this core question: How do we observe the immune system with enough precision to design better drugs? In this conversation, he explains why: 🧬 We’re shifting from iterative drug development to precision therapies powered by deep immune mapping. ⚙️ Translating discovery into medicine demands risk capital and computational infrastructure at scale. 🧠 AI is no longer a tool in the workflow; it’s the engine underneath it. Listen to the full conversation here: youtube.com/watch?v=85WL2h…
Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Digital Chemistry Innovation and Drive Development of New Materials Through State-of-the-Art Automated Molecular Design and Synthesis dlvr.it/TQvy61
Earvin "Magic" Johnson and a16z's Chris Lyons sat down for a conversation on Magic's 30 year journey from athlete to billionaire businessman, including what Magic learned from Michael Ovitz, Magic's investments in Silicon Valley and sports, why athletes should take equity over endorsements, and more. 00:00 Introduction 05:09 How Michael Ovitz became Magic's first business mentor 07:42 The art of deal making and building a Rolodex 17:30 Magic's first Silicon Valley investment: Skydio 27:00 Building a team: Get people smarter than you 29:48 The one that got away: Nike stock in 1979 37:36 Why AI is changing everything 44:36 Sports ownership: Dodgers, Commanders, Sparks, and LAFC @MagicJohnson @ChrisLyons
We raised a $150M Series B at a $1.25B valuation to fundamentally change the field of AI. Scaling is powerful, but we can't intentionally design what we don't understand.
We've identified a novel class of biomarkers for Alzheimer's detection - using interpretability - with @PrimaMente. How we did it, and how interpretability can power scientific discovery in the age of digital biology: (1/6)
⚠️ If you’re reading this, you’ve been infected* ⚠️ *~95% the human population has been infected by the Epstein-Barr Virus (EBV). Today in @Nature with @nyeo_sherry, @EMC22381830, @RyanDhindsa @SlavePetrovski, we shed some light on what happens next. nature.com/articles/s4158…
Today, we’re launching Mendra, a rare disease therapeutics company enabled by AI. We’re announcing an oversubscribed $82M Series A co-led by @OrbiMed, @8vc, and @5amVentures with participation from @Lux_Capital and @Wing_VC. Full announcement 👇 businesswire.com/news/home/2026…
Rare diseases are devastating, underfunded, and not so rare (affecting ~300 million worldwide). @MendraInc, from 8VC Build, uses AI to bypass clinical/commercial barriers and advance the most promising therapies to global availability. We’re proud to co-lead their $82M Series A.
